New drug pricing analysis reveals where PBMs and pharmacies make their money

For the first time in our existence, CMS has released drug pricing data that overlaps with the date of our launch. As we ripped open the data and examined CMS’ gift, we found some major changes in the way that the state of Ohio reported their data – and it has revealed some eye-opening information about PBM and pharmacy margins on prescription drugs. Given all the drug pricing noise out of Ohio, and the federal heat on PBM “spread pricing,” we decided to do a deep dive into what’s happening in Ohio, and how its new data provides incredible clues to determine where the money flows within the drug supply chain.

Ben LinkApril 21, 2019Ohio, Medicaid, spread pricing, NADAC, PBM, Abilify, Aripiprazole, Ziagen, Abacavir, Nexium, Esomeprazole, Invega, Paliperidone, Crestor, Rosuvastatin, Protopic, Tacrolimus, Plaquenil, hydroxychloroquine, Gleevec, Imatinib, Xeloda, Capecitabine, Viagra, Sildenafil, Revatio, Reyataz, Atazanavir, Valcyte, Valganciclovir, Viread, Tenofovir, CVS, Prilosec, Omeprazole, Suboxone, Buprenorphine-Naloxone